{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=2", "query": { "condition": "Solid Malignancy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Solid+Malignancy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T14:34:07.571Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06521554", "title": "A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "NVL-330", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvalent Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2024-07-18", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 17, "location_summary": "Irvine, California • Sacramento, California • Stanford, California + 13 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06521554" }, { "nct_id": "NCT02722954", "title": "A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "Demcizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 29, "start_date": "2016-01", "completion_date": "2017-05-19", "has_results": false, "last_update_posted_date": "2020-08-11", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 5, "location_summary": "Denver, Colorado • Ann Arbor, Michigan • New York, New York + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02722954" }, { "nct_id": "NCT07356453", "title": "A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "FORX-428", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "FoRx Therapeutics AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2025-07-22", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 8, "location_summary": "Palo Alto, California • San Francisco, California • Grand Rapids, Michigan + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07356453" }, { "nct_id": "NCT00057720", "title": "TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "TLK286 HCl for injection", "type": "DRUG" }, { "name": "topotecan hydrochloride for injection", "type": "DRUG" }, { "name": "doxorubicin HCl liposome injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telik", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 440, "start_date": "2003-06", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2011-07-25", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 234, "location_summary": "Little Rock, Arkansas • Baldwin Park, California • Burbank, California + 146 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00057720" }, { "nct_id": "NCT02071056", "title": "Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leptomeningeal Metastasis" ], "interventions": [], "intervention_types": [], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-05", "completion_date": "2015-11-25", "has_results": false, "last_update_posted_date": "2020-08-18", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02071056" }, { "nct_id": "NCT02679131", "title": "To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed/Refractory Solid Tumors/Hematological Malignancies" ], "interventions": [ { "name": "Belinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acrotech Biopharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2016-03", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 2, "location_summary": "Whittier, California • Canton, Ohio", "locations": [ { "city": "Whittier", "state": "California" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02679131" }, { "nct_id": "NCT00422682", "title": "A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "bsi-201 + topotecan", "type": "DRUG" }, { "name": "bsi-201 + temozolomide", "type": "DRUG" }, { "name": "bsi-201 + gemcitabine", "type": "DRUG" }, { "name": "bsi-201 + carboplatin/paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 136, "start_date": "2007-01", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2016-06-10", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Detroit, Michigan • New York, New York + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00422682" }, { "nct_id": "NCT03554473", "title": "M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Small Cell", "Lung Cancer", "Small Cell Lung Cancer" ], "interventions": [ { "name": "M7824", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT scan", "type": "DIAGNOSTIC_TEST" }, { "name": "PET scan", "type": "DIAGNOSTIC_TEST" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Antihistamines", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Epinephrine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 37, "start_date": "2018-09-11", "completion_date": "2025-03-13", "has_results": true, "last_update_posted_date": "2025-05-09", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03554473" }, { "nct_id": "NCT01453283", "title": "Tabectedin to Treat Children and Adolescents With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "4 Years to 16 Years" }, "enrollment_count": 12, "start_date": "2006-12-20", "completion_date": "2011-10-11", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01453283" }, { "nct_id": "NCT07525141", "title": "A Study of JNJ-1761981 in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "JNJ-1761981", "type": "DRUG" }, { "name": "Cetrelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Enterprise Innovation Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2026-05-18", "completion_date": "2029-01-31", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-07-23T14:34:07.571Z", "location_count": 4, "location_summary": "Jacksonville, Florida • Rochester, Minnesota • The Bronx, New York + 1 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "The Bronx", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07525141" } ] }